Von Willebrand Factor (VWF) is synthesized as a pre-proVWF precursor in which the pre-sequence directs the protein into the secretory pathway in endothelial cells and megakaryocytes-platelets. The proVWF contains an extremely large propeptide, VWFpp, that is comprised of 741 amino acids. VWFpp directs many of the important intracellular processes, regardless of whether it is a contiguous covalent part of the proVVVF (cis construct) molecule or is synthesized in trans as a separate polypeptide protein. Work done under this grant in previous years has defined many of the subtle aspects of the role of this propeptide and during this past funding cycle, some of the obligate domains and/or sequences have been more clearly delineated. These intracellular processes include multimerization, storage, and release - the latter being under the control of a regulatory system that is initiated by ligand-induced cellular activation. Within the endothelial cell there appears to be no secretory granule (WeibeI-Palade body) formed in the absence of VWF synthesis. We therefore will study further the induction of granule formation by VWF and the structural requirements necessary for this assembly. In platelets, however, in the absence of VWF, alpha granule formation is maintained and the contents of the alpha granule are much more complex than the relatively limited protein composition of the WeibeI-Palade body. Natural and site directed mutations will explore the necessary components of the full proVWF molecule and initial studies will be undertaken using plasmid and viral vectors to induce VWF synthesis, multimerization, storage, and release in cells and animals deficit in VWF synthesis ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL033721-17
Application #
6891282
Study Section
Special Emphasis Panel (ZRG1-HP (03))
Program Officer
Link, Rebecca P
Project Start
1984-07-01
Project End
2008-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
17
Fiscal Year
2005
Total Cost
$340,204
Indirect Cost
Name
Medical College of Wisconsin
Department
Pediatrics
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Shi, Q; Schroeder, J A; Kuether, E L et al. (2015) The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies. J Thromb Haemost 13:1301-9
Flood, Veronica H; Schlauderaff, Abraham C; Haberichter, Sandra L et al. (2015) Crucial role for the VWF A1 domain in binding to type IV collagen. Blood 125:2297-304
Brott, David A; Katein, Anne; Thomas, Heath et al. (2014) Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury. Toxicol Pathol 42:672-83
Kanaji, S; Fahs, S A; Ware, J et al. (2014) Non-myeloablative conditioning with busulfan before hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard-Soulier syndrome. J Thromb Haemost 12:1726-32
Flood, Veronica H; Gill, Joan Cox; Friedman, Kenneth D et al. (2013) Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem 59:684-91
Jacobi, Paula M; Gill, Joan Cox; Flood, Veronica H et al. (2012) Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood 119:4543-53
Flood, V H; Gill, J C; Christopherson, P A et al. (2012) Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost 10:1425-32
Kanaji, S; Fahs, S A; Shi, Q et al. (2012) Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost 10:1646-52
Kanaji, Sachiko; Kuether, Erin L; Fahs, Scot A et al. (2012) Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy. Mol Ther 20:625-32
Madabhushi, Sri R; Shang, Chengwei; Dayananda, Kannayakanahalli M et al. (2012) von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion. Blood 119:4769-78

Showing the most recent 10 out of 59 publications